EMA/PE/0000225023 - paediatric investigation plan

efgartigimod alfa
PIPHuman

Key facts

Active substance
efgartigimod alfa
Therapeutic area
Musculoskeletal and connective tissue disorders
Decision number
EMA/PE/0000225023
PIP number
EMA/PE/0000225023
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of Sjögren's syndrome
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries

Argenx  
E-mail: regulatory@argenx.com  
Tel.  +32 93103400

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date
Compliance check done
No

Decision

Share this page